Table 3.

Types of cardiotoxicity

Type I Cardiotoxicity	Type II Cardiotoxicity
• Early Onset	• Late Onset
• Myocardial damage	• Myocardial Dysfunction
• Permanent / Irreversible	• Reversible in nature
• Dose-dependent effects	• Cumulative Dose-independent effects
• Greater association with Cardiac Dysfunction and Clinical HF	• Increased loss of contractility and less myocyte death
• Typically, with Anthracyclines (Doxorubicin), Alkylating Agents Taxanes, Topoisomerase Inhibitors, Antimetabolites	• Typically, with Trastuzumab, Bevacizumab, and other Tyrosine Kinase Inhibitors, Immunomodulatory drugs, and Proteasome inhibitors but patients may develop type I cardiotoxicity in the long run